5436-25-9 Usage
Uses
Used in Pharmaceutical Industry:
4-[5-(acetyloxy)-8,8-dimethyl-6-(3-methylbut-2-en-1-yl)-4-oxo-4H,8H-pyrano[2,3-f]chromen-3-yl]benzene-1,2-diyl diacetate is used as a prodrug for its potential pharmaceutical applications due to its complex structure and the presence of the bioactive pyrano[2,3-f]chromen-3-yl group. As a prodrug, it may be metabolized in the body to release an active compound, which could have therapeutic effects.
Used in Research and Development:
In the field of chemical research and development, 4-[5-(acetyloxy)-8,8-dimethyl-6-(3-methylbut-2-en-1-yl)-4-oxo-4H,8H-pyrano[2,3-f]chromen-3-yl]benzene-1,2-diyl diacetate serves as a subject for investigation to explore its pharmacological properties and potential uses in drug discovery. 4-[5-(acetyloxy)-8,8-dimethyl-6-(3-methylbut-2-en-1-yl)-4-oxo-4H,8H-pyrano[2,3-f]chromen-3-yl]benzene-1,2-diyl diacetate's unique structure may offer insights into new avenues for the development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 5436-25-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,3 and 6 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 5436-25:
(6*5)+(5*4)+(4*3)+(3*6)+(2*2)+(1*5)=89
89 % 10 = 9
So 5436-25-9 is a valid CAS Registry Number.
5436-25-9Relevant academic research and scientific papers
COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF
-
Paragraph 0178; 0202-0203, (2020/07/08)
The present disclosure provides, inter alia, scaffolds and compounds having the structure (I). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods for selectively killing a cancer cell, methods of modulating mTORC1/2 signaling activity in a cell, methods of modulating the activity of a Master Regulator for MycN in a subject having MycN-amplified neuroblastoma (MycNAMP NBL), methods of selectively treating or ameliorating effects of a cancer in a subject in need thereof, and platforms and methods for identifylng a compound that induces degradation of a cancer-related protein. Also provided are kits comprising a compound or a pharmaceutical composition according to the present disclosure. Methods for treating cancers and methods for modulating MYC Master Regulators using other compounds are also provided.
